Twitter Beğeni Hilesi

The study results suggest that orthogonal MS testing is critical to identify MSI-H in PC and patients with MSI-H PC should be treated with immune checkpoint blockade therapy. ja.ma/4dTHral Catherine O’Connor Eileen M O’Reilly

Such an awesome team and so much great work going on! Congratulations!👏🏼👏🏼👏🏼

Having so much fun working with all of you! A team!

Great explanation and encouraging results Dr. Park! Wungki Park, MD MS

Best ⚡️talk for last!! Incredible presentation + poster on how hepcidin-mediated iron sequestration limits CD8+ tumor infiltrating lymphocytes in PDAC Joshua Schoenfeld 🧬😊

Mary Helen Larsen is our #inspiring clinical trial 👩🏼‍⚕️RN who has been one of the most essential teammates in our clinic MSKCC Center for Pancreatic Cancer Research She is an amazing person with the most compassion, passion, and talent! Yet always with humility. So proud to have her as our team member Memorial Sloan Kettering Cancer Center

The POLAR Study: Pembrolizumab With Olaparib for Metastatic Pancreatic Cancer docwirenews.com/post/the-polar…

Truly exceptional. The article doesn’t mention the dozens of mentees at all stages of training who she has taken under her wing throughout her career (myself being one). Through her mentees and her work, thousands of patients across the world have benefited.

An exceptional oncologist, exceptional researcher, exceptional clinician, and an exceptional person!

📺 At #ESMO24, Wungki Park, MD MS discussed the POLAR study and compared the trial's results to its predecessor, the POLO trial. 👉 The study investigated #olaparib with #pembrolizumab in patients with metastatic #pancreatic cancer: buff.ly/4eT9kjg

An important single institution study led by Eileen M O’Reilly from Memorial Sloan Kettering Cancer Center in JNCI Adjuvant Modified FOLFIRINOX for Resected Pancreatic Adenocarcinoma (PDAC): Clinical Insights and Genomic Features from a Large Contemporary Cohort academic.oup.com/jnci/advance-a… With all

Just a daily reminder that your patient can be Iron Deficient but not anemic. Thanks. Bye. #Hematology #TeamIron 🩸

Adjuvant mFOLFIRINOX for Resected Pancreatic Adenocarcinoma (PDAC): Clinical Insights and Genomic Features from a Large Contemporary Cohort academic.oup.com/jnci/article-a… Congrats to Fergus Keane Catherine O’Connor Fiyinfolu (Folu) Balogun Drew Moss for very thoughtful compilation synthesis of data!

Congratulations Fergus Keane Catherine O’Connor Fiyinfolu (Folu) Balogun Drew Moss Eileen M O’Reilly and all our other amazing collaborators!

Excited to be in Houston for #SITC2024 with my mentor Wungki Park, MD MS and to present our small cohort study looking at chemoimmunotherapy for treatment of metastatic Pancreatic Neuroendocrine Carcinoma!

Rising 💫Drew Moss shares our experience MSK Department of Medicine in 1L chemoimmunotherpy in pancreatic neuroendocrine carcinoma (PanNEC): significantly high ORR (100%, N=5/5) & survival (mOS 33.6m vs 16.1m). Maybe we should test this in 1L!? Rohit Thummalapalli Diane Reidy-Lagunes #SITC24

Wungki Park, MD MS Drew Moss MSK Department of Medicine Rohit Thummalapalli Diane Reidy-Lagunes Society for Immunotherapy of Cancer Eileen M O’Reilly Memorial Sloan Kettering Cancer Center Tae-Hyung Kim A team!!! Go Drew Moss!!! 🕺😊✨🤩

Congrats 🎊🎉🍾 Benoit JC Rousseau for Steven Rosenberg Award. How amazing~!! Meeting friends and alumni is always the highlight at conferences #SITC2024 MSK Department of Medicine Drew Moss Society for Immunotherapy of Cancer

Congratulations Benoit JC Rousseau on the award and marathon!